124 related articles for article (PubMed ID: 23661154)
21. Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer.
Ulybina YM; Kuligina ES; Mitiushkina NV; Rozanov ME; Ivantsov AO; Ponomariova DN; Togo AV; Levchenko EV; Shutkin VA; Brenister SI; Devilee P; Zhivotovsky B; Hirvonen A; Imyanitov EN
Cancer Lett; 2009 Jun; 278(2):183-191. PubMed ID: 19203830
[TBL] [Abstract][Full Text] [Related]
22. A Study of the Impact of Death Receptor 4 (DR4) Gene Polymorphisms in Alzheimer's Disease.
Edgünlü TG; Ozge A; Yalın OÖ; Kul S; Erdal ME
Balkan Med J; 2013 Sep; 30(3):268-72. PubMed ID: 25207117
[TBL] [Abstract][Full Text] [Related]
23. Death receptor 4 variants and colorectal cancer risk.
Frank B; Shanmugam KS; Beckmann L; Hemminki K; Brenner H; Hoffmeister M; Chang-Claude J; Burwinkel B
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):2002-5. PubMed ID: 17035413
[TBL] [Abstract][Full Text] [Related]
24. Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population.
Aksoy-Sagirli P; Cakmakoglu B; Isbir T; Kaytan-Saglam E; Kizir A; Topuz E; Berkkan H
Anticancer Res; 2011 Jun; 31(6):2225-9. PubMed ID: 21737645
[TBL] [Abstract][Full Text] [Related]
25. DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus.
Wu S; Meng Q; Zhang C; Sun H; Lu R; Gao N; Yang H; Li X; Aschner M; Chen R
Int J Cancer; 2018 Jul; 143(2):289-297. PubMed ID: 29446085
[TBL] [Abstract][Full Text] [Related]
26. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
27. Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians.
Mittal RD; Srivastava P; Mittal T; Verma A; Jaiswal PK; Singh V; Mandal RK; Mandhani A
Eur J Surg Oncol; 2011 Aug; 37(8):727-33. PubMed ID: 21700414
[TBL] [Abstract][Full Text] [Related]
28. DR4-Ser424
Lee H; Oh Y; Jeon YJ; Lee SY; Kim H; Lee HJ; Jung YK
Cancer Res; 2019 Jun; 79(11):2839-2852. PubMed ID: 30987996
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome.
Li K; Yang P; Zhao M; Hou S; Du L; Zhou H; Kijlstra A
Mol Vis; 2009 May; 15():955-61. PubMed ID: 19452015
[TBL] [Abstract][Full Text] [Related]
30. A study of TRAIL receptors in squamous cell carcinoma of the head and neck.
Teng MS; Brandwein-Gensler MS; Teixeira MS; Martignetti JA; Duffey DC
Arch Otolaryngol Head Neck Surg; 2005 May; 131(5):407-12. PubMed ID: 15897419
[TBL] [Abstract][Full Text] [Related]
31. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
32. Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death.
Park KJ; Lee CH; Kim A; Jeong KJ; Kim CH; Kim YS
J Biol Chem; 2012 Jan; 287(5):3313-25. PubMed ID: 22158615
[TBL] [Abstract][Full Text] [Related]
33. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis factor gene polymorphisms in Tunisian patients with non-small cell lung cancer.
Kaabachi S; Kaabachi W; Rafrafi A; Belkis H; Hamzaoui K; Sassi FH
Clin Lab; 2013; 59(11-12):1389-95. PubMed ID: 24409675
[TBL] [Abstract][Full Text] [Related]
35. Association of Three Single Nucleotide Polymorphisms in MTR and MTRR Genes with Lung Cancer in a Turkish Population.
Aksoy-Sagirli P; Erdenay A; Kaytan-Saglam E; Kizir A
Genet Test Mol Biomarkers; 2017 Jul; 21(7):428-432. PubMed ID: 28537809
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women.
Martinez-Ferrandis JI; Rodríguez-López R; Milne RL; González E; Cebolla E; Chirivella I; Zamora P; Arias JI; Palacios S; Cervantes A; Díez O; Benitez J; Armengod ME
Cancer Biomark; 2007; 3(2):89-93. PubMed ID: 17522430
[TBL] [Abstract][Full Text] [Related]
37. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.
Aguilera DG; Das CM; Sinnappah-Kang ND; Joyce C; Taylor PH; Wen S; Hasselblatt M; Paulus W; Fuller G; Wolff JE; Gopalakrishnan V
J Neurooncol; 2009 Jul; 93(3):303-18. PubMed ID: 19148581
[TBL] [Abstract][Full Text] [Related]
38. Levamisole enhances DR4-independent apoptosis induced by TRAIL through inhibiting the activation of JNK in lung cancer.
Qiao X; Wang C; Wang W; Shang Y; Li Y; Ni J; Chen SZ
Life Sci; 2020 Sep; 257():118034. PubMed ID: 32621923
[TBL] [Abstract][Full Text] [Related]
39. Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.
Yao W; Oh YT; Deng J; Yue P; Deng L; Huang H; Zhou W; Sun SY
J Biol Chem; 2016 Oct; 291(41):21694-21702. PubMed ID: 27576686
[TBL] [Abstract][Full Text] [Related]
40. Expression of tumor necrosis factor-related apoptosis-inducing ligand death receptors DR4 and DR5 in human nonmelanoma skin cancer.
Omran OM; Ata HS
Am J Dermatopathol; 2014 Sep; 36(9):710-7. PubMed ID: 24212133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
